On September 2, 2026, Pandanus Associates Inc. bought 509,000 shares of MEDLIVE at an average of HKD 7.4323 per share, involving about HKD 3.78 million.
Prior to the acquisition, Pandanus Associates Inc.'s long position in MEDLIVE was 66.50 million shares, representing 8.98%; following the acquisition, the holding changed to 67.01 million shares, with the long position ratio rising to 9.05%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.